+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A prospective, randomized study of inhaled prostacyclin versus nitric oxide in patients with residual pulmonary hypertension after pulmonary endarterectomy



A prospective, randomized study of inhaled prostacyclin versus nitric oxide in patients with residual pulmonary hypertension after pulmonary endarterectomy



General Thoracic and Cardiovascular Surgery 65(3): 153-159



Pulmonary endarterectomy (PEA) is an effective treatment for chronic thromboembolic pulmonary hypertension (CTEPH), but postoperative residual hypertension leads to in-hospital mortality. Inhaled epoprostenol sodium (PGI2) and NO are administered for pulmonary hypertension after cardiothoracic surgery. This prospective study provides the first comparative evaluation of the effects of inhaled PGI2 and NO on pulmonary hemodynamics, systemic hemodynamics, and gas exchange in patients developing residual pulmonary hypertension after PEA. Thirteen patients were randomized to receive either NO (n = 6) or PGI2 (n = 7) inhalation when pulmonary hypertension persisted after weaning from cardiopulmonary bypass. Hemodynamic and respiratory variables were measured before inhalation of the agent (T0); 30 min (T1), 3 h (T2), and 6 h after inhalation (T3); and the next morning (T4). The NO dose was started at 20 ppm and gradually tapered until extubation, and PGI2 was administered at a dose of 10 ng kg-1 min-1. In both groups, mean pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR) significantly decreased over time until T4 (mean PAP: p < 0.0001; PVR: p = 0.003), while mean systemic arterial blood pressure significantly increased (p = 0.028). There were no significant between-group differences in patient characteristics, cardiac index, left atrial pressure, or ratio of arterial oxygen tension to fraction of inspired oxygen. There were no in-hospital deaths. Both inhaled PGI2 and NO significantly reduced PAP and PVR without adverse effects on systemic hemodynamics in patients who developed residual pulmonary hypertension after PEA. Inhaled PGI2 can be offered as alternative treatment option for residual pulmonary hypertension.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057088776

Download citation: RISBibTeXText

PMID: 27783213

DOI: 10.1007/s11748-016-0724-2


Related references

Inhaled nitric oxide versus inhaled prostacyclin and intravenous versus inhaled prostacyclin in acute respiratory failure with pulmonary hypertension in piglets. Pediatric Research 38(2): 198-204, 1995

Inhaled nitric oxide versus prostacyclin in chronic shunt-induced pulmonary hypertension. Journal of Thoracic and Cardiovascular Surgery 126(5): 1434-1441, 2003

Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome. Heart 86(5): 553-558, 2001

Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. Journal of Cardiothoracic and Vascular Anesthesia 22(3): 406-413, 2008

A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. Yearbook of Anesthesiology and Pain Management 2010: 93-94, 2010

A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. Journal of Thoracic and Cardiovascular Surgery 138(6): 1417-1424, 2009

Randomized Comparative Study of Intravenous ATP-MgCl2 and Inhaled Nitric Oxide as Selective Pulmonary Vasodilators in Hypoxia Induced Pulmonary Hypertension. Pediatric Research 45(4, Part 2 of 2): 225a-225a, 1999

Randomized comparative study of intravenous ATP-MgCl2 and inhaled nitric oxide a selective pulmonary vasodilators in hypoxia induced pulmonary hypertension. Pediatric Research 45(4 PART 2): 225A, 1999

Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. Journal of Applied Physiology 86(4): 1160-1164, 1999

Inhaled prostacyclin versus inhaled nitric oxide in experimental pulmonary microembolism. Anesthesiology 81(3A): A641, 1994

Additive effects of inhaled prostacyclin and inhaled nitric oxide in reducing experimental pulmonary hypertension. Anesthesiology 87(3 SUPPL ): A1122, 1997

Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. Journal of Pediatrics 141(6): 830-832, 2002

Inhaled nitric oxide and inhaled prostacyclin in an animal model of pulmonary hypertension Compared efficacy and synergy. Pediatric Research 43(4 PART 2): 283A, 1998

Inhaled nitric oxide vs prostacyclin in primary pulmonary hypertension. Clinical Research 42(1): 5A, 1994

Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. American Journal of Respiratory and Critical Care Medicine 151(2 Pt 1): 384-389, 1995